• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ageing - Pipeline Review, H2 2012 Product Image

Ageing - Pipeline Review, H2 2012

  • ID: 2366383
  • December 2012
  • 52 pages
  • Global Markets Direct

Ageing – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ageing - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ageing, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ageing. Ageing - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ageing.
- A review of the Ageing products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Ageing Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Ageing 8
Ageing Therapeutics under Development by Companies 10
Ageing Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Ageing Therapeutics – Products under Development by Companies 14
Ageing Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Ageing Therapeutics Development 16
Novogen Limited 16
Novocell, Inc. 17
Bioo Therapeutics 18
Ageing – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
NV-07Alpha - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BIOO-4 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BIOO-7 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RDC-6 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RDC-1 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RDC-2 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RDC-7 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CHR-26 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RDC-8 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RDC-21 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RDC-14 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RDC-19 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RDC-20 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RDC-29 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CHR-1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CHR-3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CHR-8 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CRH-9 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CHR-12 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CHR-25 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CHR-50 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CHR-54 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Ciproxifan - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
F-899 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Laminin Peptide YIGSR - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Ageing – Product Development Milestones 50
Featured News & Press Releases 50
Aug 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-50 50
May 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-25 50
Apr 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-54 50
Feb 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-12 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for Ageing, H2 2012 8
Products under Development for Ageing – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novogen Limited, H2 2012 16
Novocell, Inc., H2 2012 17
Bioo Therapeutics, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23

List of Figures
Number of Products under Development for Ageing, H2 2012 8
Products under Development for Ageing – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos